Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138220 | 0.84 | CHRNA7 (0.57) | CHRNA7OPRM1OPRL1CHRNB2CHRNA4 | |
| SCHEMBL7610378 | 0.83 | RIPK1 (0.42) | CHRNA7TBXAS1CHRNB2CHRNA4RIPK1 | |
| Hydrochloric Acid SCHEMBL6138304 | 0.83 | CHRNA7 (0.56) | CHRNA7OPRM1OPRL1CHRNB2CHRNA4 | |
| SCHEMBL6138415 | 0.78 | CHRNB2 (0.51) | OPRM1CHRNB2CHRNA4LMNA | |
| SCHEMBL6138579 | 0.77 | CHRNB2 (0.50) | CHRNB2CHRNA4 | |
| SCHEMBL4669443 | 0.75 | SMN1; SMN2 (0.42) | OPRM1OPRL1L3MBTL1 | |
| SCHEMBL6138339 | 0.75 | CHRNB2 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL4825426 | 0.72 | HTT (0.40) | NAPRTRIPK1 | |
| SCHEMBL27699362 | 0.71 | OPRL1 (0.54) | OPRM1OPRL1 | |
| SCHEMBL5890987 | 0.70 | LMNA (0.69) | CHRNA7TBXAS1NAPRTCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1170281-B1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2005-12-21 | — | — | EP | disclosed |
| US-6943184-B2 | 1,1- and 1,2-disubstituted cyclopropane compounds | LES LABORATORIES SERVIER (FR) | 2005-09-13 | — | — | US | disclosed |
| US-20050032845-A1 | 1,1-and 1,2-disubstituted cyclopropane compounds | GOLDSTEIN SOLO (FR) | 2005-02-10 | — | — | US | disclosed |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | ADIR ET COMPAGNIE (FR) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032845-A1 | 1,1-and 1,2-disubstituted cyclopropane compounds | CHRNA1, CHRNA4, CHRNB1 | CHRNA7 23/4885TBXAS1 1092/4885NAPRT 324/4885 |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | HCAR1, CHRNA1, CNR1 | CHRNA7 36/4885TBXAS1 1206/4885NAPRT 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.